Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;11(8):4555-4571.
doi: 10.1039/d0ra10610k. Epub 2021 Jan 22.

Design, synthesis and biological evaluation of 2-quinolyl-1,3-tropolone derivatives as new anti-cancer agents

Affiliations

Design, synthesis and biological evaluation of 2-quinolyl-1,3-tropolone derivatives as new anti-cancer agents

Evgeniy A Gusakov et al. RSC Adv. 2021.

Abstract

Tropolones are promising organic compounds that can have important biologic effects. We developed a series of new 2-quinolyl-1,3-tropolones derivatives that were prepared by the acid-catalyzed reaction of 4,7-dichloro-2-methylquinolines with 1,2-benzoquinones. 2-Quinolyl-1,3-tropolones have been synthesized and tested for their anti-proliferative activity against several human cancer cell lines. Two compounds (3d and mixture B of 3i-k) showed excellent activity against six cancer cell lines of different tissue of origin. The promising compounds 3d and mixture B of 3i-k also demonstrated induction of apoptotic cell death of ovarian cancer (OVCAR-3, OVCAR-8) and colon cancer (HCT 116) cell lines and affected ERK signaling. In summary, 2-quinolyl-1,3-tropolones are promising compounds for development of effective anticancer agents.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest There are no conflicts to declare.

Figures

Scheme 1
Scheme 1. Synthesis of 2-quinolyl-1,3-tropolone derivatives 3 by an alternative pathway of the reaction.
Scheme 2
Scheme 2. Formation of the mixture of three polychloro-substituted 1,3-tropolones 3i–k.
Fig. 1
Fig. 1. Molecular structure of 5,7-di(tert-butyl)-2-(4,7-dichloro-8-methyl-2-quinolyl)-4-nitro-1,3-tropolone 3c with representation of the atoms by thermal vibration ellipsoids of 50% probability (а); a tropolone cycle in a crystal in the “bath” conformation (b).
Scheme 3
Scheme 3. Intramolecular proton transfer in compounds 3a–k.
Fig. 2
Fig. 2. Effect of 3d and mixture B of 3i–k tropolones at IC25 and IC50 concentrations on colony formation ability of ovarian and colon cancer cells. (A) OVCAR-8 under 3d treatment for 7 days; (B) OVCAR-8 under mixture B (3i–k treatment for 7 days); (C) OVCAR-3 under 3d treatment for 7 days; (D) OVCAR-3 under mixture B of treatment of 3i–k for 7 days; (E) HCT 116 under 3d treatment for 7 days; (F) HCT 116 under mixture B of treatment of 3i–k for 7 days.
Fig. 3
Fig. 3. Effect of 3d on apoptosis induction in ovarian and colon cancer cell lines. Cells were treated 3d at indicated concentration, or with DMSO. Flow cytometry results after at 0 h, 24 h, 48 h using Annexin V and propidium iodide are shown for OVCAR-8 (A), OVCAR-3 (B) and HCT 116 (C) cell line.
Fig. 4
Fig. 4. Effect of mixture B of 3i–k on apoptosis induction in ovarian and colon cancer cell lines. Flow cytometry results after at 0 h, 24 h, 48 h treatment using Annexin V and propidium iodide are shown for OVCAR-8 (A), OVCAR-3 (B) and HCT 116 (C) cell line.
Fig. 5
Fig. 5. Effect of the 3d compound on apoptosis, as measured by PARP cleavage, and ERK-signaling pathway in OVCAR-8, OVCAR-3 and HCT 116 cell lines. Cells were treated with 3d compound for 0, 12, 24 and 48 hours, and western blot analysis was done. (A) OVCAR-8 cell line; (B) OVCAR-3 cell line; (C) HCT 116 cell line.
Fig. 6
Fig. 6. Effect of the mixture B of 3i–k compound on apoptosis, as measured by PARP cleavage and ERK-signaling pathway in OVCAR-8, OVCAR-3 and HCT 116 cell lines. Cells were treated with mixture B of 3i–k compound for 0, 12, 24 and 48 hours. Western blot analysis: (A) OVCAR-8 cell line; (B) OVCAR-3 cell line; (C) HCT 116 cell line.

Similar articles

Cited by

References

    1. Siegel R. L. Miller K. D. Jemal A. Ca-Cancer J. Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Muñoz-Galván S. Felipe-Abrio B. García-Carrasco M. Domínguez-Piñol J. Suarez-Martinez E. Verdugo-Sivianes E. M. Espinosa-Sánchez A. Navas L. E. Otero-Albiol D. Marin J. J. Jiménez-García M. P. García-Heredia J. M. Quiroga A. G. Estevez-Garcia P. Carnero A. J. Exp. Clin. Cancer Res. 2019;38:234. doi: 10.1186/s13046-019-1245-5. - DOI - PMC - PubMed
    1. Bray F. Ferlay J. Soerjomataram I. Siegel R. L. Torre L. A. Jemal A. Ca-Cancer J. Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Guan L. Y. Lu Y. Discov. Med. 2018;26(144):219–229. - PubMed
    1. Brasseur K. Gévry N. Asselin E. Oncotarget. 2017;8:4008–4042. doi: 10.18632/oncotarget.14021. - DOI - PMC - PubMed

LinkOut - more resources